Floatz logo

GBM6-AD

Glioma, Astrocytic

Jennie TaylorPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Glioma, Astrocytic cohort.

Asset / SponsorPhaseRating
Carboplatin
Oliver Jonas
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2BB

View all 40 →

Same molecule, other indications

GBM6-AD is also rated in:

low-grade astrocytomaDormant
CC
Indicative ·
47 / 100
View asset →
oligoastrocytomaDormant
CC
Indicative ·
47 / 100
View asset →
OligodendrogliomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →